Global Viral Vector Manufacturing Market Projected to Grow at 20.5% CAGR, Reaching $17.42 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Viral Vector Manufacturing Industry Market Size Be by 2025?
In recent times, the market size for viral vector manufacturing has noticeably expanded. The sector, which is valued at $6.93 billion in 2024, is forecasted to increase to $8.26 billion in 2025 with a compound annual growth rate (CAGR) of 19.1%. Factors contributing to this historic growth include advancements in gene therapy pipelines, successful clinical trials and approvals, heightened investment in biopharmaceuticals, and a surge in genetic disorders.

What's the Long-Term Growth Forecast for the Viral Vector Manufacturing Market Size Through 2029?
In the coming years, the market size of viral vector manufacturing is projected to experience considerable growth. It is set to reach "$17.42 billion in 2029", growing at a compound annual growth rate (CAGR) of 20.5%. The growth observed in the forecast period could be credited to broader applications in the field of oncology, worldwide collaborations in gene therapy research, and increasing adoption of viral vectors in the development of vaccines as well as ongoing clinical trials and commercialization. Trends to look forward to in the forecast period are technological advancements in vector production, the rise of next-generation vectors, adherence to regulations and standardization, partnerships and collaborations, and the international expansion of production facilities.

View the full report here:
https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

What Are the Key Growth Drivers Fueling the Viral Vector Manufacturing Market Expansion?
The surge in the occurrences of cancer and infectious diseases is anticipated to drive the expansion of the viral vector manufacturing market. Infectious diseases are triggered by a virus or its toxic compound and are transferred to a susceptible host through interaction with an infected individual, animal, or object. Cancer encompasses a wide array of diseases that can erupt in any organ or tissue of the body when rogue cells overmultiply, breach their natural barriers to seize nearby organs, and metastasize to other organs. Tumor antigens, or proteins on tumor cells, are generated through viral vectors to stimulate the body's defensive response against cancer. Viral vectors have been employed as vaccines against a plethora of infectious diseases in pre-clinical and clinical studies. For example, in July 2024, the Australian Institute of Health and Welfare, a government organization based in Australia, reported a significant annual increase in diagnosed cancer cases from 160,570 in 2022 to 164,694 in 2023 in Australia, illustrating the escalating prevalence of cancer in the nation. Additionally, in August 2024, the UK Health Security Agency, an executive agency based in the UK, recorded 368 measles cases in 2023 in England, up sevenfold from 53 cases in 2022, with the West Midlands and London contributing to 44% and 33% of the cases respectively. Hence, the escalating incidence of cancer and infectious diseases is fueling the expansion of the viral vector manufacturing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

What Long-Term Trends Will Define the Future of the Viral Vector Manufacturing Market?
The viral vector manufacturing market is experiencing a noteworthy trend: product innovation. Some of the main players in this market are using this strategy to maintain their market position. For instance, in August 2022, the science and technology organization based in Germany, Merck KGaA, unveiled their latest innovation - the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. They were among the pioneering contract development and manufacturing organizations and technology inventors to offer a comprehensive viral vector manufacturing suite, which includes AAV, Lentiviral, CDMO, CTO, and development process. Leveraging this novel platform, biopharmaceutical enterprises can decrease both the duration and costs associated with process development, while speeding up the timeline to clinical manufacturing.

How Is the Viral Vector Manufacturing Market Segmented?
The viral vector manufacturing market covered in this report is segmented -

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types
2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases
3) By Workflow: Upstream Processing, Downstream Processing
4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research
5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Subsegments:
1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26
2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others
3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others
4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others
5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12398&type=smp

Which Companies Are Leading the Charge in Viral Vector Manufacturing Market Innovation?
Major companies operating in the viral vector manufacturing market include Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., AGC Biologics, Ultragenyx Pharmaceutical Inc., Novasep Holding SAS, Aldevron LLC, Oxford Biomedica plc, LakePharma Inc., Voyager Therapeutics Inc., Mustang Bio Inc., Regenxbio Inc., VGXI Inc., BioNTech IMFS GmbH, FinVector Oy, Vigene Biosciences Inc., Univercells Technologies, Sirion-Biotech GmbH, Cevec Pharmaceuticals GmbH, Batavia Biosciences BV.

Which Regions Are Leading the Global Viral Vector Manufacturing Market in Revenue?
North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12398

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert: Saumya Sahay: Americas +1 310-496-7795: Asia +44 7882 955267 & +91 8897263534: Europe +44 7882 955267: Email: saumyas@tbrc.info: The Business Research Company - www.thebusinessresearchcompany.com: Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.